

XVII CONVENTION SCIENTIFICA

RIVA DEL GARDA (TN) • 11-13 MARZO 2013



## SCIENTIFIC PROGRAMME

Monday, 11<sup>th</sup> March 2013

| 10.00 – 14.00 | Registration and poster setting up   |
|---------------|--|
| 14.15 – 14.30 | Welcome Sala 1000  |
| 14.30 – 15.00 | <b>Opening address</b><br>Lucia Monaco (Fondazione Telethon)   |
| 15.00 – 15.30 | LECTURE  |
|               | An introduction to the International Rare Diseases Research Consortium (IRDiRC)                                    |
|               | Irene Norstedt (European Commission, Brussels, Belgium) (Talk 1)   |
| 15.30 – 17.00 | PLENARY SESSION 1 – Genes and mechanisms of Intellectual Disabilities: paving the way for potential therapies      |
|               | Chairpersons: Han Brunner, Maria Passafaro   |
|               | Intellectual Disability: lessons from 500 diagnostic exomesHan Brunner (Nijmegen, The Netherlands)(Talk 2)         |
|               | The X-linked Intellectual Disability protein TSPAN7 regulates excitatory synapse development and AMPAR trafficking |
|               | Maria Passafaro (Milan, Italy) (Talk 3)  |
|               | FMR1 expression and FMRP function as possible targets of pharmacotherapy in the Fragile X Syndrome                 |
|               | Giovanni Neri (Rome, Italy) (Talk 4)   |
|               | Molecular bases and in vitro modeling of CdkI5 dependent infantile neurological disorders                          |
|               | Vania Broccoli (Milan, Italy) (Talk 5)   |
| 17.00 – 17.30 | Coffee break   |

- 17.30 19.00 **POSTER SESSION 1**
- 19.00 20.00
   O.Ma.R. Journalism Award
   Sala 1000

   Organized by the Osservatorio Malattie Rare, Fondazione Telethon and Orphanet Italia with the collaboration of the National Rare Diseases Centre (CNMR). http://www.premiomalattierare.it/
   Sala 1000

20.00 - 21.00

Welcome cocktail

## Tuesday, 12<sup>th</sup> March 2013

| 08.30 – 09.00 | Registration and poster setting up   |    |  |  |
|---------------|--|----|--|--|
| 09.00 – 10.30 | PLENARY SESSION 2 – Therapeutic strategies for Mendelian disorders Sala 100  | 00 |  |  |
|               | Chairpersons: Luis Galietta, Ennio Ongini (Nicox - Milan, Italy - and Rare Partners)   |    |  |  |
|               | Pharmacological strategies to rescue chloride transport in Cystic Fibrosis<br>Luis Galietta (Genoa, Italy) (Talk 6)  |    |  |  |
|               | Exploiting artificial nucleases for targeted transgene integration in human<br>Hematopoietic Stem Cells and induced Pluripotent Stem Cells derived from<br>normal donors and SCID-X1 patients<br>Angelo Lombardo (Milan, Italy) (Talk 7) |    |  |  |
|               | High Content Screening Facility at TIGEM: pharmacological approaches to treat rare genetic diseases  |    |  |  |
|               | Diego Medina (Naples, Italy) (Talk 8)  |    |  |  |
|               | A computational strategy to discover pharmacological chaperones with<br>therapeutic potential for Retinitis Pigmentosa<br>Francesca Fanelli (Modena, Italy) (Talk 9)   |    |  |  |
| 10.30 – 11.00 | Coffee break   |    |  |  |
| 11.00 – 12.30 | POSTER SESSION 2   |    |  |  |
| 12.30 – 13.00 | PICTURE OF TELETHON SCIENTISTStaken by Filippo Sbalchierogathering point: registration desk  |    |  |  |
| 13.00 - 14.00 | Buffet Lunch   |    |  |  |
| 14.00 – 15.00 | KEYNOTE LECTURE Sala 1000  |    |  |  |
|               | TIGEM goes translationalAndrea Ballabio (Naples, Italy)(Talk 10)   |    |  |  |
|               | Imagining new therapies for patients with Rare Diseases: Shire HGT and   |    |  |  |
|               | <b>TIGEM translate the future</b> Arthur Tzianabos (Shire - Lexington, MA, USA)(Talk 11)   |    |  |  |
| 15.00 – 16.00 | PLENARY SESSION 3 – Advances in clinical trials  |    |  |  |
|               | Chairpersons: Robertson Parkman (Los Angeles, CA, USA), Luigi Naldini (Milan, Italy)   |    |  |  |
|               | The development of Givinostat for the treatment of Duchenne Muscular<br>Dystrophy: from the animal to the clinic   |    |  |  |
|               | Paolo Bettica (Italfarmaco – Cinisello Balsamo, Italy), (Talk 12)<br>Eugenio Mercuri (Rome, Italy)   |    |  |  |
|               | Phase I/II clinical trial of Hematopoietic Stem Cell gene therapy for the treatment of Metachromatic Leukodystrophy<br>Alessandra Biffi (Milan, Italy) (Talk 13)   |    |  |  |
|               | Clinical trial of Hematopoietic Stem Cell gene therapy for Wiskott-Aldrich   |    |  |  |
|               | SyndromeAlessandro Aiuti (Milan, Italy)(Talk 14)   |    |  |  |
|               |  |    |  |  |

|               | An interactive session engaging all Telethon scientists in tackling the hurdles of translating laboratory research to the clinic |  |  |  |  |
|---------------|--|--|--|--|--|
|               | Moderators: Robertson Parkman (Los Angeles, CA, USA),<br>Helen Heslop (Houston, TX, USA)   |  |  |  |  |
|               | Speakers:  | Luigi Naldini (Milan), Alberto Auricchio (Naples), Grazia Valsecchi<br>(University of Milano-Bicocca, Milan), Alessandro Aiuti (Milan), Paolo Bettica<br>(Italfarmaco – Cinisello Balsamo) |  |  |  |
| 17.00 – 17.30 |  | Coffee break   |  |  |  |

16.00 – 17.00 ROUND TABLE – Navigating the Valley of Death

*17.30 – 19.00* **POSTER SESSION 3** 

09.00 - 10.30 PARALLEL SESSIONS A-B

 19.00 – 20.00
 SPECIAL EVENT
 Sala 300

 The Executive Director of the American Society for Cell Biology meets young investigators
 Stefano Bertuzzi (ASCB - Bethesda, MD, USA)

 Wine and Cheese
 Wine the American Society for Cell Biology meets young the second sec

## Wednesday, 13<sup>th</sup> March 2013

| 10.00 |   |                       |
|-------|---|-----------------------|
|       | A- Cardiomyopathy - failure and success   | Sala 1000             |
|       | Chairpersons: Daniel Garry, Silvia Priori   |                       |
|       | Emerging therapies for DMD Cardiomyopathy<br>Daniel Garry (Minneapolis, MN, USA)                            | (Talk 15)             |
|       | <b>Channelopathies: moving toward gene therapy</b><br>Silvia Priori (Pavia, Italy)                          | (Talk 16)             |
|       | Melusin gene therapy: an innovative approach to prevent<br>Cardiomyopathies<br>Guido Tarone (Torino, Italy) | Familial<br>(Talk 17) |
|       | Inherited Cardiomyopathies: from phenotype-based to genetic-based<br>Eloisa Arbustini (Pavia, Italy)        | nosology<br>(Talk 18) |
|       | B- Decoding an engineering marvel: insights from genetic Renal Disea  | ses                   |
|       | Chairpersons: Gregory Germino, Antonella De Matteis   | Sala 300              |
|       | On the edge of glory? Polycystic Kidney Disease research as a r   | model for             |
|       | moving from bench to bedside<br>Gregory Germino (Bethesda, MD, USA)   | (Talk 19)             |
|       | <b>Uromodulin and chronic diseases of the kidney</b><br>Luca Rampoldi (Milan, Italy)                        | (Talk 20)             |
|       | Cell biology and pharmacology of Lowe Syndrome<br>Antonella De Matteis (Naples, Italy)                      | (Talk 21)             |
|       | CLC-5, an endosomal chloride – proton exchanger mutated in Dent's I   | Disease: a            |
|       | biophysical perspective<br>Michael Pusch (Genoa, Italy)   | (Talk 22)             |

10.30 - 11.00

11.00 – 13.00 PARALLEL SESSIONS C-D

Coffee break

| 11.00 - 15.00 | PARALLEL SESSIONS C-D  |                         |  |  |
|---------------|--|-------------------------|--|--|
|               | C- Trial readiness in Neuromuscular Diseases   | ala 1000                |  |  |
|               | Chairpersons: Jeffrey Chamberlain, Rossella Tupler   |                         |  |  |
|               | Therapeutic potential of AAV-microdystrophin vectors for gene the<br>Duchenne Muscular Dystrophy   | rapy of                 |  |  |
|               | Jeffrey Chamberlain (Seattle, WA, USA)   | (Talk 23)               |  |  |
|               | Facioscapulohumeral Muscular Dystrophy: a walk on the dark side<br>(epi)genome<br>Davide Gabellini (Milan, Italy)  | of the<br>(Talk 24)     |  |  |
|               | From the bench to the clinic: what we have learnt from the Italian National  |                         |  |  |
|               | Registry for Facioscapulohumeral Muscular Dystrophy<br>Rossella Tupler (Modena, Italy)   | (Talk 25)               |  |  |
|               | Trial readiness in Peripheral Neuropathies: the Charcot-Marie-Tooth  | Disease                 |  |  |
|               | <b>pathway</b><br>Davide Pareyson (Milan, Italy)   | (Talk 26)               |  |  |
|               | Trial readiness in Peripheral Neuropathies: developing a unifying treatment  |                         |  |  |
|               | strategy<br>Carla Taveggia (Milan, Italy)  | (Talk 27)               |  |  |
|               | D- Blood Disorders: from genetics to genetic therapies   | Sala 300                |  |  |
|               | Chairpersons: Punam Malik, Giuliana Ferrari  |                         |  |  |
|               | Mutations in the 5'UTR of ANKRD26 result in a "new" form of Inherited<br>Thrombocytopenia that predisposes to Leukemia and is characterized by the<br>presence in platelets and megakaryocytes of a "new" cell structure |                         |  |  |
|               | Carlo Balduini (Pavia, Italy)  | (Talk 28)               |  |  |
|               | Hepcidin at the crossroad between Hemochromatosis and genet<br>Deficiency  | ic Iron                 |  |  |
|               |  | (Talk 29)               |  |  |
|               | RNA-based therapeutic approaches for Blood Coagulation Factor Define   | ciencies                |  |  |
|               | caused by splicing mutations<br>Mirko Pinotti (Ferrara, Italy)   | (Talk 30)               |  |  |
|               | Gene therapy for non-lethal disorders: the paradigm of Beta-Thalassemi<br>Giuliana Ferrari (Milan, Italy)  | i <b>a</b><br>(Talk 31) |  |  |
|               | Genetic therapy for Hemoglobinopathies: from the bench to the bedside<br>Punam Malik (Cincinnati, OH, USA)   | (Talk 32)               |  |  |
| 13.00 – 13.30 | LATE BREAKING NEWS   |                         |  |  |
|               | A highly secreted sulfamidase engineered to cross the blood-brain corrects brain lesion of mice with mucopolysaccharidoses type IIIA Alessandro Fraldi (Naples, Italy)   | barrier                 |  |  |

Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice Andrea Graziani (Novara, Italy)

Molecular function of Ubiad1, a gene associated to Schnyder Crystalline Corneal Dystrophy (SCCD) Vera Mugoni (Torino, Italy)

## 13.30 – 14.00 POSTER PRIZE AWARD AND CLOSING REMARKS